After solanezumab – where does Alzheimer’s disease research go from here?

A few weeks ago, pharmaceutical giant Eli Lilly announced that their latest Phase II trial for a drug named solanezumab, which is designed to flush beta-amyloid protein out of the brain and thereby ameliorate the symptoms of Alzheimer’s disease, had been a failure. This is a huge blow to conventional Alzheimer’s disease research because it […]

from The Evolution and Medicine Review http://ift.tt/2hwIMfn